🟢 100/100

This product looks safe

  • No ingredients exceed tolerable upper intake levels
  • 50% of ingredients have research evidence
A Label Compliance Grade

Product Label

📸

Have a supplement label? Find it here.

Upload a photo of any supplement label to search our database of 92,312 products.

Label Data

3 Capsule(s) Serving Size
90 Servings
Other Combinations Product Type
50% Evidence Coverage

Supplement Facts — Evidence Check

25 mg (125% DV)
✅ 1.8× RDA — within safe limits 📚 193 studies (Tier A: 5, B: 63)
RDA 14mg This product: 25mg UL 35mg
KETO FAT BURNING BLEND
290 mg

Other Ingredients

Gelatin Microcrystalline Cellulose Maltodextrin Silica Zanthoxylum piperitum Cellulose Oryza sativa wax Magnesium Stearate Stearic Acid Titanium Dioxide

Label Claims — Verification

Nutrient
All Other
Structure/Function
All Other (97% of products) Structure/Function (86% of products) Nutrient (36% of products)

Target Groups

Adult (18 - 50 Years)

Product Information

📋 Directions for Use

Suggested Use: Take 1 serving (3 capsules) daily. For optimal fat loss results take 2 servings (6 capsules) daily. For added convenience, you may split the dose between meals by taking 1-2 capsules with breakfast, lunch and dinner.

Take 3-6 capsules of KETO-XT(TM) with 1 capsule of ROXYLEAN(TM) daily.

⚠️ Warnings & Precautions

Caution: KETO-XT(TM) contains the B vitamin niacin. Niacin may cause temporary flushing, tingling, skin reddening, and sensations of heat, especially if taken on an empty stomach. This is a natural and harmless reaction.

Warnings: Not intended for use by persons under age 18. Do not exceed recommended dose. Do not take for more than eight (8) consecutive weeks.

This product should not be taken by pregnant or lactating women.

Get the consent of a licensed physician before using this product, especially if you are taking medication, have a medical condition, or thinking about becoming pregnant.

KEEP THIS PRODUCT AND ALL SUPPLEMENTS OUT OF THE REACH OF CHILDREN.

Additional Information

Please read entire label before use.

† When combined with a proper exercise and nutrition regimen. Statements based on early-stage independent 3rd party in vivo and / or in vitro model scientific research data findings.

Rev. 01-001-KXT001 07/12

Non-Stim Weight Loss*†

Non-Stim Weight Loss*†

{3 white capsules}

Product Details

UPC / SKU 8 51780 00445 6
DSLD Entry Date 2013-02-25
Product Type Other Combinations
Form Capsule
Brand BPI
DSLD ID 18630
Data Updated 2026-04-11

Research Evidence

241 Research Sources
55 Avg Quality Score
113 Meta Analysis
75 Systematic Review
32 Rct
11 Clinical Trial
3 Other
3 Regulatory Source
1 Cochrane Review
1 Narrative Review
1 Openfda Safety
A Niacin for primary and secondary prevention of cardiovascular events
Meta Analysis The Cochrane database of systematic reviews 2017
A Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
Meta Analysis BMJ (Clinical research ed.) 2013
A Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117,411 patients
Meta Analysis BMJ (Clinical research ed.) 2014
A A terminal metabolite of niacin promotes vascular inflammation and contributes to cardiovascular disease risk
Meta Analysis Nature medicine 2024
A Meta-analysis and imputation refines the association of 15q25 with smoking quantity
Meta Analysis Nature genetics 2010
A Genome-wide meta-analyses identify multiple loci associated with smoking behavior
Meta Analysis Nature genetics 2010
A Antidepressants for smoking cessation
Meta Analysis The Cochrane database of systematic reviews 2014
A Topical azelaic acid, salicylic acid, nicotinamide, sulphur, zinc and fruit acid (alpha-hydroxy acid) for acne
Meta Analysis The Cochrane database of systematic reviews 2020
B Assessment of the Role of Niacin in Managing Cardiovascular Disease Outcomes: A Systematic Review and Meta-analysis
Meta Analysis JAMA network open 2019
B Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis
Meta Analysis JAMA 2016
View all evidence for Niacin →

Compare Similar Products

View all Niacin products →